Identification of potential barriers to treatment should be explored in future trials, Dr. Thrall said. Also, variables not measured in this study, such as performance status, could further help to explain treatment decisions in these women with advanced epithelial ovarian cancer.
Dr. Thrall and Dr. Carney said that they had no relevant financial disclosures.